Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Launched by EXCYTE BIOPHARMA LTD · May 30, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called YK012 for people with moderate to severe systemic lupus erythematosus (SLE), which is an autoimmune disease that can cause inflammation and damage to various parts of the body. The main goals of the study are to understand how safe YK012 is, how well it works, and how it is processed in the body. The trial is currently not recruiting participants, and it will include adults aged 18 to 65 who have been diagnosed with SLE for at least six months and have certain lab test results indicating active disease.

To participate in the trial, individuals must meet specific criteria, such as having a confirmed diagnosis of SLE, showing high disease activity, and being on stable treatment for their condition. It's important to note that some people may not be eligible, including those with certain allergies, other autoimmune diseases, or recent treatments that could interfere with the study. Participants will be closely monitored throughout the trial, which will involve scheduled visits and treatments. Overall, this study aims to explore a promising new option for managing SLE symptoms and improving patients' quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 to 65 years (inclusive) at screening, regardless of sex
• • Meet the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE, with a confirmed SLE diagnosis for at least 24 weeks at screening
• • Positive for anti-dsDNA antibody and/or antinuclear antibody (ANA) and/or anti-Smith antibody at screening, as determined using the local laboratory's reference ranges at the study site
• • High disease activity at screening, defined as: Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥7
• • Receiving stable Standard of Care (SoC) at screening, including either oral glucocorticoid monotherapy at a stable dose (≤40 mg/day prednisone or equivalent) or combined with antimalarial drugs at a stable dose for at least 2 weeks prior to screening, or a single immunosuppressant at a stable dose for at least 4 weeks (only one immunosuppressant is permitted)
• • Capable of understanding and voluntarily participating in this clinical trial, having provided written informed consent, and able to comply with scheduled visits, treatments, examinations, and other study procedures.
• Exclusion Criteria:
• • Known allergy to monoclonal antibodies or exogenous human immunoglobulins, or hypersensitivity to the investigational drug or any of its components;
• • Received rituximab or any B-cell depleting agents within 6 months prior to enrollment, or B-cell stimulatory factor inhibitors (e.g., belimumab, telitacicept) within 3 months prior to randomization (subjects with B-cell counts above the lower limit of normal may be enrolled);
• • Received TNF inhibitors, interleukin receptor blockers, other small molecules or biologics within 3 months prior to enrollment;
• • Received intravenous immunoglobulins or plasmapheresis within 3 months prior to enrollment;
• • Used Total Glucosides of White Paeony Capsules, Zhengqing Fengtongning, Colquhounia Root Tablets, Tripterygium wilfordii tablets, or other traditional Chinese medicines/herbal preparations containing Tripterygium wilfordii within 1 month prior to enrollment;
• • Received live or attenuated vaccines within 1 month prior to enrollment;
• • Has autoimmune diseases other than SLE (except secondary Sjögren's syndrome);
• • History of malignancy, except for completely resected basal cell or squamous cell skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of breast, or papillary thyroid cancer that has been disease-free for at least 5 years;
• • Clinically significant cardiovascular/cerebrovascular diseases within 6 months prior to screening: The New York Heart Association Classification (NYHA) Class III or IV heart failure, unstable angina, myocardial infarction, severe arrhythmias, or stroke;
• • History of non-SLE conditions requiring oral/intravenous/intramuscular/subcutaneous corticosteroid therapy (\>2 weeks) within 6 months prior to enrollment;
• • Active tuberculosis at screening or untreated latent tuberculosis;
• • Active infections including: systemic antibiotic-treated infections within 2 weeks prior to enrollment; unresolved Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), Herpes Simplex Virus (HSV),Varicella-Zoster Virus (VZV) infections;
• • Within 8 weeks prior to enrollment: severe lupus nephritis (defined as proteinuria \>6g/24 hours or serum creatinine \>2.5mg/dL \[221μmol/L\]), active nephritis requiring protocol-prohibited medications, needing hemodialysis, or receiving prednisone ≥100mg/day (or equivalent) for ≥14 days;
• • Within 8 weeks prior to enrollment: Central Nervous System (CNS) disorders (including epilepsy, psychosis, organic brain syndrome, cerebrovascular accident, encephalitis, CNS vasculitis) caused or not caused by SLE;
• * Laboratory abnormalities defined as:
• • Marked hematological abnormalities
• • Abnormal liver function indicators
• • Impaired renal function
• • Notable immunological deviations
• * Positive virology tests for:
• • HIV antibodies
• • HBsAg+; or HBsAg-/HBcAb+ with detectable HBV-DNA
• • HCV Ab+ with detectable HCV-RNA
• • Treponema pallidum antibodies+ (except if negative for Rapid Plasma Reagin or Toludine Red Unheated Serum Test);
• • Had major surgery within 4 weeks prior to enrollment or planned during study;
• • Participation in other interventional clinical trials within 4 weeks prior to enrollment;
• • Pregnant/lactating women; women of childbearing potential with positive pregnancy test; or subjects planning pregnancy within 12 months after study completion; unwilling to use ≥1 contraceptive method during the study and for 12 months thereafter;
• • Other conditions deemed by investigators to preclude study participation.